# Disposable Endoscope Market

> Disposable Endoscope Market Research Report: Size, Share, Trend Analysis By Product Type (Rigid Endoscope, Flexible Endoscope, Video Endoscope), By Applications (Gastroenterology, Urology, Pulmonology, ENT, Cardiology), By End Users (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), By Distribution Channel (Direct Sales, Distributors, Online Sales) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 8.0%
- **2025:** USD 3.66 Billion
- **2035:** USD 7.90 Billion
- **Key Players:** Ambu A/S, Boston Scientific, Olympus Corporation, Karl Storz, Verathon (Roper), Fujifilm Holdings, HOYA (Pentax Medical), Hunan Vathin Medical

**Report ID:** MRFR/HC/10245-HCR · **Pages:** 128 · **Author:** Rahul Gotadki & Satyendra Maurya · **Last Updated:** September 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/disposable-endoscope-market-11765

---

## Market Summary

According to MRFR analysis, the Disposable Endoscope Market Size was valued at USD 2.6 Billion in 2024. The market is projected to grow from USD 3.074 Billion in 2025 to USD 16.37 Billion by 2035, registering a CAGR of 18.2% during the forecast 2025–2035. North America led the market with over 46.15% share, generating around USD 1.2 billion in revenue.  
 
The Disposable Endoscope Market is growing due to increasing focus on infection prevention, rising adoption of minimally invasive procedures, and expanding burden of chronic diseases. Key trends include transition toward single-use devices, advancements in imaging technology, and growing healthcare investments aimed at improving patient safety, procedural efficiency, and reducing cross-contamination risks. 
 
The World Health Organization reports that hundreds of millions of patients are affected by healthcare-associated infections globally each year, reinforcing the need for improved infection control measures such as single-use medical devices.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Cross-contamination liability and HAI reporting | 1.8 | North America, Europe | Short-term (≤2 yr) | [8] |
| Reimbursement codification for single-use procedures | 1.5 | North America | Short-term (≤2 yr) | [2] |
| CMOS sensor cost decline and optical parity | 1.3 | Global | Medium-term (2–4 yr) | [3] |
| Sterile processing labour shortage | 1.1 | North America, Europe | Medium-term (2–4 yr) | [9] |
| Ambulatory surgical centre expansion | 1.2 | North America, Asia-Pacific | Medium-term (2–4 yr) | [10] |
| FDA duodenoscope transition guidance | 0.9 | North America | Long-term (≥4 yr) | [1] |
| ICU bronchoscopy volume growth | 0.7 | Global | Long-term (≥4 yr) | [6] |

### Cross-Contamination Liability and Infection Reporting

Beyond just compensation, infection-control economics sped up uptake. Even after verified reprocessing, reusable endoscopes may still harbor microbiological contamination, especially when intricate channels and drying constraints result in residual-risk locations. Patient-to-patient carryover and reliance on reprocessing quality between procedures are eliminated with single-use scopes. This benefit is particularly significant in urology, bronchoscopy, and critical care settings where patients are frequently immunocompromised or susceptible to infection. Disposable endoscopes are becoming less of a convenience item and more of a risk-reduction tool as hospitals monitor device-associated contamination occurrences and tighten infection-prevention procedures.

### Reimbursement Codification for Single-Use Procedures

Interest was transformed into orders by payment certainty. In certain Medicare Administrative Contractor jurisdictions, 2024 payment rates covered about 85% of device procurement costs, and CMS assigned Category III CPT codes for flexible ureteroscopy and single-use bronchoscopy, providing ambulatory operators with a defensible revenue line [2]. Disposables are now billed by establishments that used to absorb them as overhead. The CMS stance has been largely mirrored by commercial payers, and the planned Category I transfer would eliminate any residual coverage discretion.

### CMOS Sensor Cost Decline and Optical Parity

Imaging economics changed the category. Chip-on-tip CMOS modules that cost roughly USD 95 per unit in 2020 now ship near USD 55 in volume, a decline of about 40% driven by smartphone-supply-chain spillover [3]. That compression let manufacturers hold list prices while adding 400,000-pixel resolution, wider field of view, and improved low-light performance. Blinded reader studies now report diagnostic concordance above 90% between single-use and reusable bronchoscopes for airway inspection tasks, removing the last clinical objection for routine work.

### Sterile Processing Labour Shortage

Staffing scarcity is a quiet but powerful driver in the Disposable Endoscope Market. The Healthcare Sterile Processing Association reports vacancy rates near 17% across U.S. central sterile departments, with median time-to-fill exceeding 90 days [9]. Each reusable flexible scope consumes roughly 45 to 76 minutes of technician time per cycle under AAMI ST91 protocols. Removing that burden lets administrators redeploy scarce technicians to surgical instrument throughput, a labour arbitrage that shows up directly in departmental budgets.

### Ambulatory Surgical Centre Expansion

Site-of-care migration compounds unit volume. U.S. ambulatory surgical centre counts grew from roughly 5,400 in 2018 to more than 6,300 by 2024, with gastroenterology and urology among the fastest-growing specialty categories [10]. These facilities rarely operate full sterile processing departments, and floor space converted from reprocessing to procedure bays generates incremental case revenue. Private-equity roll-up operators favour predictable per-case consumable pricing over capital equipment depreciation, making disposables structurally attractive to the channel.

### FDA Duodenoscope Transition Guidance

Regulatory pressure reshaped the highest-value product line. The FDA's recommendation that facilities transition away from fixed-endcap duodenoscopes toward disposable-component or fully disposable designs, reinforced through successive safety communications, effectively set a replacement clock on installed reusable fleets [1]. Post-market surveillance studies found contamination rates on reprocessed duodenoscopes exceeding 5% for high-concern organisms. With average selling prices four to six times those of single-use bronchoscopes, duodenoscope conversion carries disproportionate revenue weight.

### ICU Bronchoscopy Volume Growth

Critical care demand remains structurally elevated. Global ICU bronchoscopy procedure volumes rose an estimated 22% between 2019 and 2024, driven by ventilator-associated pneumonia surveillance, difficult-[airway management](https://www.marketresearchfuture.com/reports/airway-management-market-8472), and post-viral airway clearance protocols [6]. Bedside bronchoscopy in isolation rooms is where reusable logistics fail most visibly — transport, decontamination and turnaround add hours. Single-use devices arrive sterile at the bedside, and several intensivist societies now list them as preferred for suspected multidrug-resistant colonisation.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Per-procedure cost premium vs amortised fleets | -1.6 | Global | Short-term (≤2 yr) | [11] |
| Medical plastic waste and decarbonisation mandates | -1.0 | Europe | Medium-term (2–4 yr) | [12] |
| Therapeutic channel and accessory limitations | -0.9 | Global | Medium-term (2–4 yr) | [13] |
| Image quality gaps in high-acuity procedures | -0.7 | Global | Short-term (≤2 yr) | [14] |
| Polymer resin price and supply concentration | -0.5 | Asia-Pacific, Europe | Long-term (≥4 yr) | [15] |

### Per-Procedure Cost Premium Versus Amortised Fleets

Disposables are still taken into account by high-volume centers. Reusable bronchoscopy is estimated by peer-reviewed cost modeling to cost between USD 155 and USD 240 per procedure once depreciation, reprocessing labor, and repair are factored in, compared to USD 210 to USD 320 for single-use procedures [11]. The reusable curve prevails above about 400 procedures per scope each year. Due to their hectic schedules, academic institutions continue to be slow converters in the disposable endoscope market.

### Medical Plastic Waste and Decarbonisation Mandates

In Europe, sustainability policies are detrimental to the category. According to life-cycle estimates, a single-use bronchoscope has about 2.4 kg CO2-equivalent, compared to 0.5 kg for a reprocessed equivalent [12]. NHS England's net-zero supplier roadmap mandates carbon reduction commitments from equipment makers. Price and embodied carbon are being given more weight on procurement scorecards. Disposable device caps in non-critical indications have been enforced by a number of Nordic health authorities.

### Therapeutic Channel and Accessory Limitations

Device architecture constrains addressable procedures. Most commercial single-use [gastroscopes](https://www.marketresearchfuture.com/reports/gastroscopes-market-4481) offer working channels between 2.0 and 2.8 mm with limited suction, insufficient for large-polyp resection, haemostasis clipping or complex stone basketing [13]. Accessory ecosystems built around reusable platforms do not always mate reliably with disposable ports. Until channel diameter and articulation improve, reimbursement-rich therapeutic volume stays with reusable systems.

### Image Quality Gaps in High-Acuity Procedures

Optical ceilings persist at the diagnostic frontier. Single-use platforms rarely offer narrow-band imaging, magnification endoscopy or high-definition chromoendoscopy, and comparative studies report lower adenoma detection sensitivity for subtle mucosal lesions [14]. Screening colonoscopy programmes measured on detection-rate benchmarks cannot accept that trade-off. The gap narrows annually, but it remains a hard barrier in oncology surveillance.

### Polymer Resin Price and Supply Concentration

Input volatility pressures margin. Medical-grade polycarbonate and thermoplastic elastomer pricing swung more than 30% between 2021 and 2024, with a concentrated supplier base across a small number of Asian and European plants [15]. Sterilisation capacity — particularly ethylene oxide, now under tightening emissions regulation — adds a second bottleneck. Manufacturers absorbing these swings face compressed gross margins that slow price-led adoption.

## Opportunities

## Disposable Endoscope Market Opportunities

### Emerging-Market Penetration Through Localised Manufacturing

Asia-Pacific and Latin American tertiary systems represent the largest untapped volume pool for the Disposable Endoscope Market. India's Production Linked Incentive scheme for medical devices allocated roughly USD 400 million toward domestic manufacturing, lowering landed cost for locally produced single-use scopes by an estimated 25% against imports [16]. Chinese provincial volume-based procurement tenders have begun listing disposable bronchoscopes as separate categories. Manufacturers that localise assembly rather than exporting finished goods capture both tender eligibility and tariff relief.

### Procedure Data Capture and Analytics Monetisation

Every disposable scope ships with a controller, and every controller is a data node. Cloud-connected platforms already archive procedure video, timestamps, and operator identifiers, creating a longitudinal dataset that supports credentialing analytics, quality benchmarking and algorithm training. Vendors can license de-identified imaging corpora to AI developers or sell subscription analytics to hospital quality departments, shifting revenue from a pure consumable model toward recurring software income.

### Therapeutic Platform Expansion

Channel engineering is the highest-value unsolved problem. Prototypes accepting 1.8 mm and larger accessories point toward disposable ERCP, polypectomy, and ureteric stone extraction — procedures carrying reimbursement several multiples above diagnostic work [13]. Manufacturers that solve articulation stiffness and suction at that diameter will unlock a segment currently held entirely by reusable incumbents, and will pull compatible disposable accessory sales alongside.

### Capital-Light Subscription and Bundled Service Models

Procurement psychology favours operating expenditure. Bundling the controller, monitor, trolley and an annual scope commitment into a single per-case subscription removes the capital approval hurdle that stalls disposable programmes in budget-constrained facilities. Structures of this kind already exist in ambulatory urology and can be extended across product lines, converting one-time hardware placements into multi-year contracted revenue with predictable renewal economics.

### Low-Carbon and Recyclable Device Engineering

Sustainability pressure is also a differentiation opening. Mono-material housings, take-back recycling programmes and reduced packaging can cut per-device carbon footprint by an estimated 35% while satisfying European procurement scorecards [12]. Vendors publishing verified life-cycle assessments gain tender advantage in markets where disposables face policy resistance, converting a restraint into a competitive moat.

## Future Outlook

## Disposable Endoscope Market Future Outlook

### Embedded AI Detection as a Platform Differentiator

Algorithmic assistance will migrate from premium reusable towers into disposable ecosystems. Computer-aided detection systems have demonstrated adenoma detection rate improvements of roughly 14 percentage points in randomised colonoscopy trials, and the processing now runs on the controller rather than the scope [20]. Because single-use vendors control the controller and refresh software independently of hardware, they can deploy model updates across an installed base in weeks. That inverts the traditional advantage held by capital-equipment incumbents tied to multi-year hardware cycles.

### Razor-and-Blade Economics and Installed Base Lock-In

Controller placement will determine market structure by 2030. Each deployed tower creates a proprietary consumable annuity, and switching costs rise once clinical staff trains on a specific interface and image profile. Manufacturers are already placing controllers at or below cost against multi-year scope commitments, mirroring the economics of surgical stapling and infusion pumps. Expect consolidation pressure as vendors lacking installed-base scale find consumable pricing squeezed in competitive tenders.

### Carbon Accounting and Circular Design Requirements

Sustainability reporting becomes procurement-relevant rather than reputational. Health systems representing more than 60 national commitments under the WHO-supported climate-resilient health care initiative have pledged emissions reduction targets that include supply chain scope 3 accounting [21]. Vendors will need verified life-cycle assessments, mono-material designs and functioning take-back logistics to remain tender-eligible in Europe by the early 2030s. Manufacturers treating this as engineering rather than marketing will hold share in the region where the Disposable Endoscope Market faces its stiffest policy headwind.

### Manufacturing Regionalisation and Cost Deflation

Supply chains reorganise around tariff and resilience pressure. Concentration of sterilisation and injection-moulding capacity has drawn regulatory attention following ethylene oxide emissions actions in the United States, accelerating investment in alternative sterilisation modalities and geographically distributed plants [15]. Regionalised production in India, Mexico and Eastern Europe should compress delivered cost by an estimated 15% to 20% by 2032. Lower unit pricing extends the addressable procedure base into mid-volume centres that currently favour reusables.

## Segment Insights

## Disposable Endoscope Market Segmentation

### By Product

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Gastroscopes | USD 0.97 Billion | Outpatient upper-GI diagnostic volume |
| Bronchoscopes | 29.7% share | ICU bedside procedures and airway management |
| Duodenoscopes | 9.8% CAGR (2026–2035) | ERCP cross-contamination regulation |
| Other Product Types | 31.0% share | Ureteroscopy, cystoscopy, rhinolaryngoscopy |

Bronchoscopes lead the Disposable Endoscope Market because critical care is where reusable logistics break down most visibly — isolation-room transport and reprocessing turnaround simply cannot match a sterile-packaged device at the bedside. Teaching hospitals reinforce that position by using single-use units for resident training, eliminating scheduling contention over shared equipment. Duodenoscopes grow fastest from a smaller base as regulatory pressure retires elevator-mechanism reusables, and their premium pricing gives each conversion outsized revenue weight.

### By Application Type

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Gastroenterology | 37.5% share | ERCP contamination concern, outpatient colonoscopy |
| Pulmonology | 9.5% CAGR (2026–2035) | Pneumonia diagnostics and lung cancer staging |
| Urology | 18.2% share | Stone management and ureteroscopy volume |
| Other Application Types | USD 0.64 Billion | ENT, gynaecology, emergency airway |

Gastroenterology holds the largest application share in the Disposable Endoscope Market, sustained by high absolute procedure counts and by the reprocessing anxiety that ERCP specifically generates. GI suites report denser scheduling once turnaround dependency disappears, which matters in high-deductible markets competing on appointment availability. Pulmonology grows fastest as transbronchial needle aspiration and lung-cancer staging volumes rise, with clinicians citing contamination risk and downtime as the decisive procurement variables.

### By Procedure Type

| Segment | Metric | Primary Demand Driver |
| --- | --- | --- |
| Diagnostic | 7.3% CAGR (2026–2035) | Simplified single-channel device architecture |
| Therapeutic | 28.5% share (2025) | Emerging wide-channel disposable platforms |

Diagnostic work dominates volume within the Disposable Endoscope Market because inspection procedures need no complex channel architecture, letting manufacturers mass-produce at cost points that undercut loaded reusable economics. Administrators also value the simplified tray setup, which measurably reduces room-turnover time in facilities running short on nursing staff. Therapeutic procedures remain the smaller contributor but carry the higher unit price, and prototypes accepting larger accessories signal where margin expansion will come from after 2028.

### By End User

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Hospitals | 65.7% share | Infection-prevention dashboards, training standardisation |
| Ambulatory Surgical Centres | 10.4% CAGR (2026–2035) | Category III CPT adoption, zero-reprocessing footprint |
| Other End Users | USD 0.43 Billion | Specialty clinics, emergency and transport services |

Hospitals remain the core buyer in the Disposable Endoscope Market, embedding single-use metrics into infection-prevention dashboards and using standardised devices to make resident training reproducible across rotations. Ambulatory surgical centres grow fastest because they never built reprocessing departments and can convert that absent footprint into billable procedure bays. Predictable per-case pricing also suits private-equity operators modelling consolidated facility returns, which is why the channel pulls procedures out of inpatient settings.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 42.2% share | Reimbursement expansion, ASC buildout, duodenoscope conversion |
| Europe | USD 0.97 Billion | MDR compliance, sustainability-weighted procurement |
| Asia-Pacific | 9.1% CAGR (2026–2035) | Local manufacturing, tender-driven volume, ICU capacity |
| South America | USD 0.19 Billion | Private hospital modernisation, urology caseload |
| Middle East & Africa | 3.7% share | Sovereign health infrastructure, medical tourism hubs |
| Total | USD 3.66 Billion | — |

### North America

| Country | Metric | Key Driver |
| --- | --- | --- |
| US | 87.4% of region | CPT code coverage and HAI reporting mandates |
| Canada | 8.1% of the region | Provincial infection-prevention procurement standards |
| Mexico | 4.5% of the region | Private hospital network expansion |

North America anchors the Disposable Endoscope Market on regulatory and payment infrastructure that no other region matches. Public reporting under CMS Hospital-Acquired Condition Reduction Programme ties reimbursement to infection performance, giving administrators a direct financial reason to eliminate reprocessing risk [8]. Canadian adoption moves through provincial health authority tenders that increasingly specify single-use devices for immunocompromised and multidrug-resistant cases. Mexico's growth concentrates in Monterrey and Mexico City private networks serving cross-border patients, where accreditation standards mirror U.S. practice.

### Europe

| Country | Metric | Key Driver |
| --- | --- | --- |
| Germany | 24.6% of region | Hospital hygiene ordinance enforcement |
| UK | 19.8% of region | NHS endoscopy backlog recovery programmes |
| France | 15.2% of the region | ANSM device vigilance and ERCP protocols |
| Italy | 10.7% of region | Regional tender consolidation |
| Spain | 8.9% of region | Ambulatory day-surgery expansion |
| Nordic Countries | 7.4% of region | Infection-prevention leadership, sustainability caps |
| Russia | 5.1% of region | Domestic substitution procurement |
| Rest of Europe | 8.3% of region | Central European hospital modernisation |

European demand carries a policy contradiction that shapes vendor strategy. Medical Device Regulation recertification raised compliance cost per device family substantially, favouring manufacturers with scale and pushing smaller reusable-scope refurbishers out of the channel [7]. Against that, national decarbonisation commitments and the European Green Deal's circular-economy targets place disposables under scrutiny. German hospital hygiene ordinances remain the strongest single adoption driver, while Nordic authorities have imposed the continent's tightest restrictions on non-essential single-use consumption.

### Asia-Pacific

| Country | Metric | Key Driver |
| --- | --- | --- |
| China | 10.2% CAGR | Volume-based procurement listing disposables separately |
| India | 11.4% CAGR | PLI scheme and tertiary hospital expansion |
| Japan | 6.8% CAGR | Ageing population and GI screening programmes |
| South Korea | 8.4% CAGR | National cancer screening endoscopy volume |
| ASEAN | 9.6% CAGR | Medical tourism accreditation standards |
| Rest of Asia-Pacific | 7.9% CAGR | Public hospital capacity investment |

Asia-Pacific converts demographic scale into the fastest regional expansion. China's national gastric cancer screening initiatives push upper-GI endoscopy volumes past 40 million procedures annually, a base against which even low single-use penetration produces large absolute unit numbers [17]. India's incentive scheme has attracted domestic assembly partnerships with three multinational manufacturers since 2023, cutting import dependence. Japanese adoption trails on cost grounds but accelerates in bronchoscopy, where reprocessing staff shortages mirror Western patterns.

### South America

| Country | Metric | Key Driver |
| --- | --- | --- |
| Brazil | 61.3% of region | ANVISA registration streamlining, private network scale |
| Argentina | 17.8% of region | Urology stone-management caseload |
| Rest of South America | 20.9% of region | Chilean and Colombian hospital accreditation |

South American uptake concentrates in private hospital groups that compete on accreditation credentials. Brazil's ANVISA has shortened registration timelines for Class II endoscopic devices, reducing time-to-market for entrants by several months and widening the supplier field [18]. Public systems remain price-constrained, so growth clusters in São Paulo and Rio de Janeiro networks serving insured populations. Argentine demand tracks urology, where high stone-disease prevalence sustains ureteroscopy volume.

### Middle East & Africa

| Country | Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 31.6% of region | Vision 2030 health sector transformation |
| UAE | 24.2% of region | Medical tourism and JCI accreditation density |
| South Africa | 16.4% of region | Private hospital group standardisation |
| Egypt | 11.5% of region | Universal health insurance rollout |
| Rest of MEA | 16.3% of the region | Gulf and North African tertiary buildout |

Middle East and Africa demand follows sovereign capital rather than reimbursement policy. Saudi Arabia's health sector transformation programme has funded new tertiary facilities specifying single-use endoscope devices in original equipment tenders, bypassing the reprocessing infrastructure decision entirely [19]. UAE facilities pursuing Joint Commission International accreditation adopt disposables to simplify audit documentation. African adoption outside South Africa remains limited by price, though donor-funded infection-control programmes create pockets of demand.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration sits in the medium band. Market Research Future estimates a Herfindahl-Hirschman Index between 900 and 1,150 for 2025, with the top five suppliers holding an estimated 52% to 58% of global revenue. Structure differs sharply by product line: single-use bronchoscopy is consolidated around two or three suppliers with mature installed controller bases, while ureteroscopy and cystoscopy remain fragmented across regional specialists and Chinese contract manufacturers competing on price. Reusable-scope incumbents entered late but bring distribution depth and hospital relationships that pure-play disposable firms cannot replicate quickly. Expect acquisition of niche urology and ENT specialists as majors fill portfolio gaps.

| Company | Est. Revenue Share Range | Key Offerings for Disposable Endoscope Market | Strategic Positioning |
| --- | --- | --- | --- |
| Ambu A/S | ~20–24% | Single-use bronchoscopes, cystoscopes, duodenoscopes, imaging platforms | Category originator with the deepest installed controller base |
| Boston Scientific | ~13–17% | Single-use duodenoscopes and ureteroscopes | Leverages GI and urology channel depth with therapeutic focus |
| Olympus Corporation | ~8–11% | Hybrid disposable-component and single-use bronchoscopes | Reusable incumbent defending share via selective conversion |
| Karl Storz | ~5–7% | Single-use cystoscopes and airway endoscopes | Surgical visualisation heritage, hospital OR relationships |
| Verathon (Roper) | ~5–7% | Single-use bronchoscopes and video laryngoscopes | Airway management adjacency, strong critical care presence |
| Fujifilm Holdings | ~4–6% | Single-use bronchoscopes, GI imaging systems | Imaging technology strength, Asia-Pacific distribution |
| HOYA (Pentax Medical) | ~3–5% | Disposable-component duodenoscopes and accessories | Regulatory-driven ERCP conversion strategy |
| Hunan Vathin Medical | ~3–5% | Single-use bronchoscopes and ureteroscopes | Cost-led volume manufacturing, emerging-market tenders |
| Flexicare Medical | ~2–4% | Single-use bronchoscopes and airway devices | Anaesthesia and respiratory channel specialist |
| Cook Medical | ~2–3% | Single-use ureteroscopes and endoscopic accessories | Accessory ecosystem integration |
| UroViu Corporation | ~1–2% | Portable single-use cystoscopy systems | Office-based urology niche, point-of-care design |

## Recent News & Developments

## Recent News & Developments

- Ambu A/S (March 2023): Launched an expanded single-use gastroenterology platform pairing a new imaging processor with wider-channel scopes, extending the company beyond airway into GI where reusable incumbents held near-total share [4]
- Boston Scientific (September 2023): Reported cumulative single-use duodenoscope procedure volume surpassing 100,000 cases, validating that regulatory-driven ERCP conversion translates into recurring consumable revenue rather than pilot activity [5]
- U.S. FDA (January 2024): Issued updated guidance reinforcing transition away from fixed-endcap duodenoscopes and clarifying premarket expectations for disposable-component designs, tightening the replacement timeline on installed reusable fleets [1]
- Olympus Corporation (June 2024): Announced a strategic investment in single-use bronchoscopy manufacturing capacity, signalling that the largest reusable incumbent now treats disposables as a defended product line rather than a competitive threat [22]
- Hunan Vathin Medical (October 2024): Secured expanded regulatory clearances across ASEAN and Middle Eastern markets for its single-use bronchoscope range, intensifying price competition in tender-driven geographies [23]
- NHS Supply Chain (February 2025): Introduced carbon-intensity weighting into flexible endoscopy procurement frameworks, requiring suppliers to submit verified life-cycle data as a condition of framework inclusion [12]
- Karl Storz (May 2025): Completed acquisition of a single-use cystoscopy specialist, adding office-based urology capability and consolidating a fragmented segment of the Disposable Endoscope Market [24]
- CMS (August 2025): Advanced review of Category I code proposals covering single-use bronchoscopy, a step that would remove remaining payer discretion and standardise reimbursement nationally [2]

## Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global sterile disposable scopes and single-use flexible endoscopy devices, including associated imaging controllers, segmented by product, application type, procedure type, end user and region |
| Study Period | 2021–2035 (Historical 2021–2024; Base Year 2025; Forecast 2026–2035) |
| CAGR | 8.0% (2026–2035) |
| Market Size Checkpoints | USD 3.66 Billion (2025); USD 3.95 Billion (2026); USD 5.81 Billion (2031); USD 7.90 Billion (2035) |
| Fastest Growing Segments | Duodenoscopes (Product); Pulmonology (Application Type); Therapeutic (Procedure Type); Ambulatory Surgical Centres (End User); Asia-Pacific (Region) |
| Companies Profiled | Ambu A/S, Boston Scientific, Olympus Corporation, Karl Storz, Verathon, Fujifilm Holdings, HOYA (Pentax Medical), Hunan Vathin Medical, Flexicare Medical, Cook Medical, UroViu Corporation |
| Valuation Currency | USD Billion, constant 2025 exchange rates |

## Frequently Asked Questions

**Q: What procedure volume threshold should a hospital use when deciding between single-use and reusable scopes?**
A: Below roughly 400 procedures per scope annually, disposables usually win on loaded cost. Above that, amortisation favours reusables unless infection liability or staffing gaps dominate the calculation [11].

**Q: How should procurement teams evaluate controller lock-in before committing to a supplier in the Disposable Endoscope Market?**
A: Model total contract value across five years, not device unit price. Controllers create switching costs through staff training and interface familiarity, so negotiate scope pricing floors and exit terms at placement.

**Q: Do single-use scopes meet the same sterility assurance standard as reprocessed devices?**
A: Single-use devices ship terminally sterilised at a 10⁻⁶ sterility assurance level, which reprocessing protocols do not guarantee. Post-market studies found contamination above 5% on reprocessed duodenoscopes [1].

**Q: What waste-handling changes does a disposable programme require?**
A: Facilities need expanded regulated medical waste capacity and, in Europe, verified life-cycle documentation for tender eligibility. Some vendors now operate take-back recycling schemes that reduce landfill volume materially [12].

**Q: Which emerging clinical uses are expanding the Disposable Endoscope Market beyond traditional suites?**
A: Office-based urology, emergency department airway management and pre-hospital transport are the fastest-emerging settings. Portable battery-powered systems remove the need for a fixed tower entirely.

**Q: How do EU Medical Device Regulation requirements affect supplier selection?**
A: Recertification costs favour manufacturers with broad portfolios and scale, thinning the smaller supplier field. Buyers should verify current certificate validity and notified body capacity before awarding multi-year frameworks [7].

**Q: What integration barriers slow adoption in the Disposable Endoscope Market?**
A: Accessory compatibility is the main obstacle, since instruments built for reusable ports may not seat reliably in disposable channels. Electronic health record video-archiving integration is the second common friction point [13].


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/disposable-endoscope-market-11765*